215 related articles for article (PubMed ID: 14598055)
1. High-dose intravenous immunoglobulin in inflammatory myopathies: experience based on controlled clinical trials.
Dalakas MC
Neurol Sci; 2003 Oct; 24 Suppl 4():S256-9. PubMed ID: 14598055
[TBL] [Abstract][Full Text] [Related]
2. The role of high-dose immune globulin intravenous in the treatment of dermatomyositis.
Dalakas MC
Int Immunopharmacol; 2006 Apr; 6(4):550-6. PubMed ID: 16504918
[TBL] [Abstract][Full Text] [Related]
3. Controlled studies with high-dose intravenous immunoglobulin in the treatment of dermatomyositis, inclusion body myositis, and polymyositis.
Dalakas MC
Neurology; 1998 Dec; 51(6 Suppl 5):S37-45. PubMed ID: 9851729
[TBL] [Abstract][Full Text] [Related]
4. Limited effects of high-dose intravenous immunoglobulin (IVIG) treatment on molecular expression in muscle tissue of patients with inflammatory myopathies.
Barbasso Helmers S; Dastmalchi M; Alexanderson H; Nennesmo I; Esbjörnsson M; Lindvall B; Lundberg IE
Ann Rheum Dis; 2007 Oct; 66(10):1276-83. PubMed ID: 17277004
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic approaches in patients with inflammatory myopathies.
Dalakas MC
Semin Neurol; 2003 Jun; 23(2):199-206. PubMed ID: 12894385
[TBL] [Abstract][Full Text] [Related]
6. Clinical benefits and immunopathological correlates of intravenous immune globulin in the treatment of inflammatory myopathies.
Dalakas MC
Clin Exp Immunol; 1996 May; 104 Suppl 1():55-60. PubMed ID: 8625545
[TBL] [Abstract][Full Text] [Related]
7. Gene expression profile in the muscles of patients with inflammatory myopathies: effect of therapy with IVIg and biological validation of clinically relevant genes.
Raju R; Dalakas MC
Brain; 2005 Aug; 128(Pt 8):1887-96. PubMed ID: 15857930
[TBL] [Abstract][Full Text] [Related]
8. Downregulation of TGF-beta1 mRNA and protein in the muscles of patients with inflammatory myopathies after treatment with high-dose intravenous immunoglobulin.
Amemiya K; Semino-Mora C; Granger RP; Dalakas MC
Clin Immunol; 2000 Feb; 94(2):99-104. PubMed ID: 10637094
[TBL] [Abstract][Full Text] [Related]
9. IVIg in myasthenia gravis, Lambert Eaton myasthenic syndrome and inflammatory myopathies: current status.
Illa I
J Neurol; 2005 May; 252 Suppl 1():I14-8. PubMed ID: 15959667
[TBL] [Abstract][Full Text] [Related]
10. A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies.
Dastmalchi M; Grundtman C; Alexanderson H; Mavragani CP; Einarsdottir H; Helmers SB; Elvin K; Crow MK; Nennesmo I; Lundberg IE
Ann Rheum Dis; 2008 Dec; 67(12):1670-7. PubMed ID: 18272672
[TBL] [Abstract][Full Text] [Related]
11. Intravenous gamma globulin as first line therapy in polymyositis and dermatomyositis: an open study in 11 adult patients.
Cherin P; Piette JC; Wechsler B; Bletry O; Ziza JM; Laraki R; Godeau P; Herson S
J Rheumatol; 1994 Jun; 21(6):1092-7. PubMed ID: 7932419
[TBL] [Abstract][Full Text] [Related]
12. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis.
Dalakas MC; Illa I; Dambrosia JM; Soueidan SA; Stein DP; Otero C; Dinsmore ST; McCrosky S
N Engl J Med; 1993 Dec; 329(27):1993-2000. PubMed ID: 8247075
[TBL] [Abstract][Full Text] [Related]
13. [Immunoglobulins or plasma exchange? New treatment methods in polymyositis and dermatomyositis: plasma exchange and intravenous immunoglobulins].
Chérin P; Herson S
Ann Med Interne (Paris); 1993; 144(8):521-5. PubMed ID: 8179241
[TBL] [Abstract][Full Text] [Related]
14. Decreased expression of interleukin-1alpha, interleukin-1beta, and cell adhesion molecules in muscle tissue following corticosteroid treatment in patients with polymyositis and dermatomyositis.
Lundberg I; Kratz AK; Alexanderson H; Patarroyo M
Arthritis Rheum; 2000 Feb; 43(2):336-48. PubMed ID: 10693873
[TBL] [Abstract][Full Text] [Related]
15. Inflammatory myopathies: evaluation and management.
Greenberg SA
Semin Neurol; 2008 Apr; 28(2):241-9. PubMed ID: 18351525
[TBL] [Abstract][Full Text] [Related]
16. Difference in adhesion molecule expression (ICAM-1 and VCAM-1) in juvenile and adult dermatomyositis, polymyositis and inclusion body myositis.
Sallum AM; Kiss MH; Silva CA; Wakamatsu A; Vianna MA; Sachetti S; Marie SK
Autoimmun Rev; 2006 Feb; 5(2):93-100. PubMed ID: 16431335
[TBL] [Abstract][Full Text] [Related]
17. Treatment of idiopathic inflammatory myopathies.
Amato AA; Griggs RC
Curr Opin Neurol; 2003 Oct; 16(5):569-75. PubMed ID: 14501840
[TBL] [Abstract][Full Text] [Related]
18. Intravenous immunoglobulin in patients with anti-GAD antibody-associated neurological diseases and patients with inflammatory myopathies: effects on clinicopathological features and immunoregulatory genes.
Dalakas MC
Clin Rev Allergy Immunol; 2005 Dec; 29(3):255-69. PubMed ID: 16391401
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic options in autoimmune inflammatory myopathies (dermatomyositis, polymyositis, inclusion body myositis).
Pongratz D
J Neurol; 2006 Sep; 253 Suppl 5():V64-5. PubMed ID: 16998756
[TBL] [Abstract][Full Text] [Related]
20. Th1 and Th17 balance in inflammatory myopathies: interaction with dendritic cells and possible link with response to high-dose immunoglobulins.
Tournadre A; Porcherot M; Chérin P; Marie I; Hachulla E; Miossec P
Cytokine; 2009 Jun; 46(3):297-301. PubMed ID: 19303320
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
